Back
Rate this talk
Your peers have not rated this talk yet.
21-minute watch | Talk 3 of 5

EHA 2025

Age is not a barrier: The older patient with comorbidities

Dr Mary Ann Anderson
SYMPOSIUM
EHA

EHA 2025: Doctor, what is my best chance of a cure? A case-based approach to the evolving treatment landscape in R/R lymphomas

Read more

Talks in this series

EHA 25 Lymphoma symposium - Prof. Luminari - Welcome and Introduction
2-minute watch | Talk 1 of 5
EHA 2025
Welcome and Introduction
EHA 25 Lymphoma symposium - Prof. Luminari - Welcome and Introduction
2-minute watch
EHA 2025

Welcome and Introduction

EHA 25 Lymphoma symposium - Dr Falchi - Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
20-minute watch | Talk 2 of 5
Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
Dr Lorenzo Falchi
EHA 25 Lymphoma symposium - Dr Falchi - Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
20-minute watch

Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse

Dr Lorenzo Falchi

EHA 25 Lymphoma symposium - Dr Anderson - Age is not a barrier: The older patient with comorbidities
21-minute watch | Talk 3 of 5
Age is not a barrier: The older patient with comorbidities
Dr Mary Ann Anderson
EHA 25 Lymphoma symposium - Dr Anderson - Age is not a barrier: The older patient with comorbidities
21-minute watch

Age is not a barrier: The older patient with comorbidities

Dr Mary Ann Anderson

EHA 25 Lymphoma symposium - Dr Pennisi - Timing is of the essence: The patient with MCL on a BTKi
24-minute watch | Talk 4 of 5
Timing is of the essence: The patient with MCL on a BTKi
Dr Martina Pennisi
EHA 25 Lymphoma symposium - Dr Pennisi - Timing is of the essence: The patient with MCL on a BTKi
24-minute watch

Timing is of the essence: The patient with MCL on a BTKi

Dr Martina Pennisi

EHA 25 Lymphoma symposium - Prof. Luminari - Summary and Close
2-minute watch | Talk 5 of 5
Summary and Close
Prof. Stefano Luminari
EHA 25 Lymphoma symposium - Prof. Luminari - Summary and Close
2-minute watch

Summary and Close

Prof. Stefano Luminari

EHA 25 Lymphoma symposium - Prof. Luminari - Welcome and Introduction
2-minute watch | Talk 1 of 5
EHA 2025
Welcome and Introduction
EHA 25 Lymphoma symposium - Prof. Luminari - Welcome and Introduction
2-minute watch
EHA 2025

Welcome and Introduction

EHA 25 Lymphoma symposium - Dr Falchi - Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
20-minute watch | Talk 2 of 5
Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
Dr Lorenzo Falchi
EHA 25 Lymphoma symposium - Dr Falchi - Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse
20-minute watch

Hope for the best, plan for the worst: The patient with DLBCL at high risk of relapse

Dr Lorenzo Falchi

EHA 25 Lymphoma symposium - Dr Anderson - Age is not a barrier: The older patient with comorbidities
21-minute watch | Talk 3 of 5
Age is not a barrier: The older patient with comorbidities
Dr Mary Ann Anderson
EHA 25 Lymphoma symposium - Dr Anderson - Age is not a barrier: The older patient with comorbidities
21-minute watch

Age is not a barrier: The older patient with comorbidities

Dr Mary Ann Anderson

EHA 25 Lymphoma symposium - Dr Pennisi - Timing is of the essence: The patient with MCL on a BTKi
24-minute watch | Talk 4 of 5
Timing is of the essence: The patient with MCL on a BTKi
Dr Martina Pennisi
EHA 25 Lymphoma symposium - Dr Pennisi - Timing is of the essence: The patient with MCL on a BTKi
24-minute watch

Timing is of the essence: The patient with MCL on a BTKi

Dr Martina Pennisi

EHA 25 Lymphoma symposium - Prof. Luminari - Summary and Close
2-minute watch | Talk 5 of 5
Summary and Close
Prof. Stefano Luminari
EHA 25 Lymphoma symposium - Prof. Luminari - Summary and Close
2-minute watch

Summary and Close

Prof. Stefano Luminari

Interested in this topic?

Find more like this

  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.